¡¾µ÷¼Á¡¿±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2024Äê16¸öרҵ½ÓÊܵ÷¼Á
²é¿´: 787  |  »Ø¸´: 1

hb99doctor

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

[½»Á÷] ÇÅѪ¹ÜÎǺϿڲ¡±ä½éÈëÖÎÁÆ

Ê׶¼Ò½¿Æ´óѧ¸½Êô±±¾©°²ÕêÒ½Ôº ºú±ö

ÇÅѪ¹ÜÎǺϿÚÊǹÚ×´¶¯Âö¶¯ÂöÅÔ·ÒÆÖ²£¨CABG£©ÊõºóÔÙÏÁÕ­µÄºÃ·¢²¿Î»Ö®Ò»£¬ÆäÖÎÁÆ°üÀ¨Ò©ÎïÖÎÁÆ¡¢ÔÙ´ÎCABGºÍ¾­Æ¤¹Ú×´¶¯Âö½éÈëÖÎÁÆ£¨PCI£©¡£ÓÉÓÚÕ³Á¬Ôì³ÉµÄÊÖÊõ²Ù×÷ÄѶȴ󣬿ÉÓõÄÇÅѪ¹ÜÓÐÏÞ£¬»¼Õ߶àΪÀÏÄêÈË£¬ºÏ²¢¶àÖÖ¼²²¡£¬Î§ÊõÆÚ¼°Êõºó²¢·¢Ö¢¡¢ËÀÍöÂÊ·¢ÉúÂʸߵÈÔ­Òò£¬Ä¿Ç°¹ú¼ÊÉÏÔÙ´ÎCABGµÄ»¼Õß½ÏÉÙ£¬¶ø¹úÄÚ½öÓиö°¸±¨µÀ£¬¶øÒ©ÎïÖÎÁƸÄÉÆ֢״Ч¹ûÇ·¼Ñ¡£¾­Æ¤¹Ú×´¶¯Âö½éÈëÖÎÁÆ( PCI) Òò·çÏÕС,³É¹¦Âʸ߶ø±¸ÊÜÇàíù£¬¹ÊÒѳÉΪ´¦ÀíÇÅѪ¹ÜÎǺϿڲ¡±äµÄÖØÒªÊֶΡ£
<!--[if !supportLists]-->Ò»¡¢    <!--[endif]-->¾²ÂöÇÅѪ¹ÜÎǺϿڲ¡±äµÄ½éÈëÖÎÁÆ
  ´óÒþ¾²Âö(SVG)×÷ΪµÚÒ»¸öÓÃÓÚCABG ÊõµÄѪ¹Ü¹©Ìå, ÒòÆä½âÆÊλÖñídz, Ò×ÓÚÓÎÀë, È¡²Ä·½±ã; ÇÒÓÐ×ã¹»µÄ³¤¶È, ÊÊÓÃÓÚ¶à֧Ѫ¹Ü²¡±äµÈÓŵã, ÖÁ½ñÈÔÈ»±»¹ã·ºÊ¹ÓÃ. µ«Êõºó¾²ÂöµÄÔÙÏÁÕ­ºÍ±ÕÈûÑÏÖØÓ°ÏìÁËÆäÔ¶ÆÚͨ³©ÂÊ, Óб¨µÀÊõºó1, 5ºÍ10 ÄêµÄ¿ª·ÅÂÊ·Ö±ðΪ93%¡¢74%ºÍ41%¡£
ÔÚCABGÊõºó1¸öÔ·¢ÉúµÄSVG²¡±ä£¬Ò»°ãÓÉÓÚѪ˨Ðγɻò¼¼Êõ²Ù×÷Ô­ÒòÒýÆ𣬱íÏÖΪÇÅѪ¹Ü±ÕÈû»òÎǺϿÚÏÁÕ­£¬ CABGÊõºó1¡«12¸öÔ³öÏÖȱѪµÄÔ­Òòͨ³£ÎªÇÅѪ¹ÜÎǺϿÚÏÁÕ­£¬ÇÅѪ¹ÜÔ¶¶ËÎǺϿÚÏÁÕ­¶Ô½éÈëÖÎÁÆ·´Ó¦½ÏºÃ£¬¶øÇÅѪ¹ÜÓëÖ÷¶¯ÂöµÄ½ü¶ËÎǺϿÚÏÁÕ­³£³£´æÔÚÖÂÃܵÄÏËά×éÖ¯£¬Ê¹ÔÙÏÁÕ­·¢ÉúÂÊÔö¸ß¡£´Ëʱ£¬Ñ¡ÓöÔÇÅѪ¹Ü½éÈëÖÎÁÆЧ¹û½ÏºÃ£¬¶øÊõºó1Äê¸ù¾ÝÇé¿ö¶ø¶¨£¬Ô­Ôò¾¡Á¿ÐÐԭλѪ¹ÜPCI¡£
SVGÎǺϿڲ¡±ä°üÀ¨Ö÷¶¯Âö¿ª¿Ú²¡±äºÍÔ¶¶ËÎǺϿڲ¡±ä¡£BrilakisµÈ¶Ô91,355ÃûÐÐSVGÇÅѪ¹Ü½éÈëÖÎÁƵĻ¼Õß·ÖÎöºó·¢ÏÖ£¬½ü¶ÎÎǺϿڲ¡±äÕ¼20.3%£¬Ô¶¶ËÎǺϿڲ¡±äΪ16.2%¡£

1 SVGÖ÷¶¯Âö¿ª¿Ú²¡±ä
   Abdel-MeguidµÈ¶Ô68Ãû¾²ÂöÇÅѪ¹Ü¿ª¿Ú²¡±äµÄ»¼Õß½øÐÐPTCA»òÐýÇÐÊõ£¬½á¹ûÏÔʾ£¬ÊÖÊõ³É¹¦ÂÊΪ89.7%£¬Æ½¾ùËæ·Ã23¡À 17Ôºó£¬Ö÷Òª²»Á¼Ê¼þ£¨°üÀ¨ËÀÍö£¬Ðļ¡¹£ËÀ£¬ÑªÔËÖؽ¨»òÒòÐÄÔಡסԺÖÎÁÆ£©¡¢³öÏÖÐĽÊÍ´¡¢ËÀÍö·Ö±ðΪ64%£¬ 50%£¬ 13%£¬ÆäÖÐ10 Ãû»¼Õß³öÏÖÐļ¡¹£ËÀ£¬19Ãû»¼ÕßÐаÐѪ¹ÜÖؽ¨Êõ¡£StephanµÈÑо¿ÏÔʾ£¬¶¨ÏòÐýÇÐÊõÖÎÁÆSVG¾²ÂöÇÅѪ¹Ü¿ª¿Ú²¡±äÊÖÊõ³É¹¦Âʸߣ¬²¢·¢Ö¢µÍ£¬µ«ÔÙÏÁÕ­·¢ÉúÂʸߡ£¶¨ÏòÐýÄ¥ÊõÊÊÓÃÓÚÑÏÖظƻ¯¡¢³É½ÇµÄ¿ª¿Ú²¡±ä»¼Õß¡£Ò²Óб¨µÀ×¼·Ö×Ó¼¤¹âÖÎÁÆ206Àý¿ª¿Ú²¡±äµÄ»¼Õߣ¬ÊÖÊõ³É¹¦ÂÊΪ90%£¬×¡ÔºÆÚ¼äÖ÷Òª²¢·¢Ö¢Îª4%£¬Ëæ·Ã6Ô£¬75%δ³öÏÖÖ÷Òª²»Á¼ÐÄѪ¹Üʼþ£¬×ÜÌåµÄÔÙÏÁÕ­·¢ÉúÂÊ£¨51%µÄ»¼ÕßÐÐÔìÓ°Ëæ·Ã£©Îª39%£¬ÆäÖÐSVGÇÅѪ¹Ü¿ª¿Ú²¡±äΪ35%¡£
ÕâЩÑо¿¾ùÌáʾ£¬´«Í³µÄÇòÄÒÀ©ÕÅ¡¢×¼·Ö×Ó¼¤¹â¼°ÐýÄ¥ÊõÖÎÁÆSVG¿ª¿Ú²¡±ä£¬ÊÖÊõ²¢·¢Ö¢¼°ÔÙÏÁÕ­·¢ÉúÂʸߣ¬Ð§¹ûÇ·¼Ñ£¬¿ÉÄÜÓëÇòÄÒÀ©Õźóµ¯ÐÔ»ØËõ£¬¿ª¿Ú²¡±ä°ß¿é¸ººÉÖØÓйأ¬Ò»Ð©Ñо¿ÏÔʾ£¬Ö§¼ÜÖÃÈëÊõ£¬ÊÖÊõ³É¹¦Âʸߣ¬¶ø²¢·¢Ö¢µÍ£¬¹ÊÄ¿Ç°Ê×Ñ¡Ö§¼ÜÖÃÈëÊõÓÃÓÚ´ËÀಡ±äµÄÖÎÁÆ¡£
NordrehaugµÈ¶Ô19ÃûSVG½ü¶ËÎǺϿڲ¡±äµÄ»¼ÕßÖ²Èë×ÔÅòÕÍÐÍÖ§¼Ü£¬Ëæ·Ã9Ô£¬ÈýÃû»¼ÕßÐèÒªÔÙ´ÎѪÔËÖؽ¨£¬12Ãû»¼ÕßÖ¢×´Ã÷ÏÔ¸ÄÉÆ£¬¿ÉÄÜÓëÖ§¼ÜÓнϺõÄÈáÈíÐÔÓйء£ToutouzasµÈÔÚ18ÀýSVGÖ÷¶¯Âö¿ª¿Ú²¡±ä»¼ÕßÖÐÓ¦Óø²Ä¤Ö§¼ÜÈ¡µÃ½ÏºÃЧ¹û£¬¿ÉÄÜÓë´øĤ֧¼Ü·ÀÖ¹Ö÷¶¯Âö¿ÚÄÚĤÔöÉúÓйء£RechaviaµÈ¹²ÄÉÈë29ÀýSVGÖ÷¶¯Âö¿ª¿ÚÏÁÕ­µÄ»¼Õߣ¬Ö²ÈëPalmaz or Paimaz-SchatzÖ§¼Ü£¬Ëæ·Ã30Ì죬¾ùÎÞËÀÍö¡¢·ÇQ²¨Ðļ¡¹£ËÀ¡¢Ö§¼ÜѪ˨¼°CABG³öÏÖ£¬½øÐÐÁËƽ¾ù11¡À8ÔÂËæ·Ã£¬1Ãû»¼ÕßËÀÓÚÐÄÁ¦Ë¥½ß£¬1Ãû»¼Õß³öÏÖÐļ¡¹£ËÀ£¬24Ãû»¼Õßδ³öÏÖÖ÷Òª²»Á¼ÐÄѪ¹Üʼþ¡£Rocha-SinghµÈÒ²¶ÔÖ²Èë½ðÊôÂãÖ§¼Ü£¨Palmaz-Schatz stent£©µÄ¾²ÂöÇÅѪ¹Ü¿ª¿Ú»òԭλѪ¹Ü¿ª¿Ú²¡±äµÄ41Ãû»¼Õß½øÐÐËæ·Ã£¬Êõºó20ÃûÇÅѪ¹Ü¿ª¿Ú²¡±äµÄ»¼ÕßÐÐÔìÓ°Ëæ·Ã£¨Æ½¾ù5.8¡À1.8Ô£©£¬½á¹ûÏÔʾ£¬7Ãû»¼Õß³öÏÖÔÙÏÁÕ­¡£ÕâÓëYamasakiµÈµÄÑо¿½á¹ûÒ»Ö¡£
AhmedµÈÔÚ320ÀýSVGÖ÷¶¯Âö¿ª¿Ú²¡±ä»¼ÕßÖбȽϰ߿éÈ¥³ýÊõ£¨×¼·Ö×Ó¼¤¹â»ò¶¨ÏòÐýÇУ©ÁªºÏÖ§¼ÜÖÃÈ루133Àý£¬¹²139´¦²¡±ä£©ºÍµ¥´¿Ö§¼ÜÖÃÈ루187Àý£¬¹²201´¦²¡±ä£©µÄÁÆЧ¡£½á¹ûÏÔʾ£ºÁ½×éPCI³É¹¦ÂÊ£¨97.8% ±È 97.4%£¬P=0.40£©¡¢²¢·¢Ö¢·¢ÉúÂÊ£¨2.2% ±È 2.6%£¬P=0.24£©¡¢1ÄêTLRÂÊ£¨19.4% ±È 18.2%£¬P=0.47£©¼°ÎÞÐÄÔàʼþÉú´æÂÊ£¨69% ±È 68%£¬P=0.48£©ÎÞÏÔÖø²î±ð£¬Î´ÌåÏÖ³ö°ß¿éÈ¥³ýÁªºÏÖ§¼ÜÖ²ÈëÊõÔÚÓÅÓÚµ¥´¿Ö§¼ÜÖ²ÈëÊõ¡£ KaplanµÈ±È½Ï70ÀýSVGÖ÷¶¯Âö¿ª¿Ú²¡±ä»¼ÕßʹÓÃDES£¨37Àý£©ºÍBMS£¨33Àý£©µÄÖÎÁÆЧ¹û¡£½á¹ûÏÔʾ£ºDES×éºÍBMS×éµÄPCI³É¹¦ÂÊ·Ö±ðΪ94.6%ºÍ87.9%£»×¡ÔºÆÚ¼äµÄ·ÇQ²¨Ðļ¡¹£ËÀµÄ·¢ÉúÂÊΪ8.1% ºÍ12.1%£¨P=0.015£©£¬Ëæ·Ã1Ä꣬ÓëBMS×éÏà±È£¬DES×éTLRÂÊ£¨5.4% ±È 30.3%, P=0.015£©¡¢°ÐѪ¹ÜÔÙ´ÎѪÔËÖؽ¨ÂÊ£¨10.8% ±È 33.3%£¬P=0.045£©¼°MACEÂÊ£¨10.8% ±È 36.4%£¬P=0.024£©ÏÔÖø½µµÍ¡£
2. SVGÔ¶¶ËÎǺϿڲ¡±ä
   Ò»Ð©Ñо¿ÏÔʾ£¬PTCA¿ÉÓÃÓÚSVGÔ¶¶ËÎǺϿڲ¡±äµÄÖÎÁÆ£¬ÆäÔÙÏÁÕ­·¢ÉúÂʸߣ¬µ«µÍÓÚ½ü¶ËÎǺϿڻòÇÅѪ¹ÜÌ岿µÄ²¡±ä£¬µ«·¢ÉúÔÙÏÁÕ­µÄÔ­Òò°üÀ¨¼¼Êõ·½Ã棨Ѫ¹ÜµÄÑ¡È¡¡¢ÊÖÊõ²Ù×÷¹ý³Ì£©¡¢ÎǺϿÚÏËάÄÚĤÔöÉú¼°¶¯ÂöÖàÑù°ß¿éµÄÍË»¯µÈ¡£
DouglasµÈÑо¿ÏÔʾ£¬PTCAÖÎÁƺ󣬽ü¶ËÎǺϿڡ¢Ì岿¼°Ô¶¶ËÎǺϿÚÔÙÏÁÕ­·¢ÉúÂÊ·Ö±ðΪ50% ¡¢53%¡¢¼°18%¡£ÁíÍâÒ»ÏîÑо¿Ò²±¨µÀÔÚ44´¦ÔÙÏÁÕ­µÄ²¡±äÖУ¬¾­PTCAÊõºó£¬½ü¶Ë¡¢Ô¶¶ËÎǺϿÚÔÙÏÁÕ­·¢ÉúÂÊ·Ö±ðΪ60%ºÍ31% ¡£De FeyterµÈ·ÖÎöÁËSVGÔÙÏÁÕ­µÄ²¡Àý¼°PTCAµÄÁÆЧ£¬½á¹ûÏÔʾ£¬ ×ÜÌåÔÙÏÁÕ­·¢ÉúÂÊΪ42%£¬½ü¶Ë¿ª¿ÚºÍÔ¶¶ËÎǺϿڷֱðΪ 58% ºÍ28%¡£GrubergµÈ»Ø¹Ë·ÖÎö·¢ÏÖ£¬SVGÔ¶¶ËÎǺϿڲ¡±äPTCA£¨182Àý£©×éºÍBMS×飨77Àý£©×¡ÔºÆÚ¼äMACEÂÊÎÞÃ÷ÏÔ²îÒì¡£Ëæ·Ã17¡À14¸öÔ£¬Á½×éËÀÍöÂʺÍST¶Î̧¸ßÐÍÐļ¡¹£ËÀ·¢ÉúÂÊÒàÎÞÏÔÖø²î±ð£¬TLRÂÊÔÚPTCA×é      ÓÐÔö¸ßÇ÷ÊÆ£¨25£¥±È14£¥£¬p=0.058£©¡£ÌáʾֲÈëÖ§¼Ü½øÒ»²½½µµÍÔÙÏÁÕ­·¢ÉúÂÊ¡£
¶þ ¶¯ÂöÇÅѪ¹ÜÎǺϿڲ¡±äµÄ½éÈëÖÎÁÆ
ÈéÄÚ¶¯Âö£¨IMA£©¡¢è㶯Âö¡¢Î¸ÍøĤÓÒ¶¯Âö¡¢Æ¢¶¯ÂöºÍ¸¹±Ú϶¯ÂöµÈ¾ùÊÇ¿ÉÑ¡ÓõÄCABGÒÆÖ²¶¯ÂöѪ¹Ü£¬IMAÔòÄܱ£³Ö½ÏÍêÉƵÄÄÚĤ´Ó¶ø¼õÉÙ¾Ö²¿ÔöÉúºÍÖàÑùÓ²»¯, ²¢ÇÒÄܱ£³Ö×î´ó»úÖÆÀ´²úÉúÊæÕÅѪ¹ÜºÍ¿¹ÑªÐ¡°å¾Û¼¯µÄÇ°Áл·ËØ, Æä10 ÄêµÄͨ³©Âʱ£³ÖÔÚ95%, ÖàÑùÓ²»¯·¢ÉúÂʽö4% ,ԶСÓÚ´óÒþ¾²ÂöµÄ26%£¬IMA ¿ÉÒÔ´øµÙºÍÓÎÀëʹÓã¬IMA Ò²¿ÉÒÔË«²àʹÓÃ, IMAÅÔ·×óÇ°½µÖ§ÏÔʾÁËÆäÓÅÔ½ÐÔ,¹Ê×îΪ³£Óã¬ÆäÖÐÎǺϿÚÊÇÆäÔÙÏÁÕ­µÄ³£¼û²¿Î»£¬¶ÔÎǺϿڲ¡±äµÄ´¦ÀíÖÁ¹ØÖØÒª¡£
Ä¿Ç°Ñо¿ÏÔʾ£¬ÈéÄÚ¶¯ÂöÇÅѪ¹ÜÎǺϿڲ¡±ä½éÈëÖÎÁÆÓ¦Ê×Ñ¡PTCA£¨Percutaneous transluminal coronary  angioplasty£¬¾­Æ¤¹Ú×´¶¯ÂöÇ»ÄÚ³ÉÐÎÊõ£©Êõ¡£HearneµÈ¶Ô68ÃûLIMAÇÅѪ¹Ü»¼ÕßÐÐPTCAÊõ£¬ÆäÖÐ59Ãû»¼ÕßΪÎǺϿڲ¡±ä£¬ÊÖÊõ³É¹¦ÂÊΪ88%£¬40ÃûÎǺϿڲ¡±äµÄ»¼Õߣ¬ÆäÖÐ6Ãû»¼Õß³öÏÖÔÙÏÁÕ­£¬¶Ô58Ãû»¼Õß½øÐÐÁËƽ¾ù17ÔµÄËæ·Ã£¬78% ¼ÓÄôóÐÄѪ¹ÜЭ»áÐĽÊÍ´·Ö¼¶ÎªCanadian I »òII¼¶£¬1Ãû»¼Õßâ§ËÀ£¬1Ãû»¼Õß5Äêºó³öÏÖ·ÇQÐļ¡¹£ËÀ£¬ 2Ãû»¼ÕßÐзֱðÔÚ³öÔººó1ÔºÍ7ÔÂÐаÐѪ¹ÜÖؽ¨Êõ¡£´æ»îÂÊΪ92%£¬ÌáʾPTCAÖÎÁÆLIMAÇÅѪ¹ÜÎǺϿڲ¡±ä³¤ÆÚÊÇ°²È«ÓÐЧµÄ¡£GrubergµÈ¶Ô174Àý£¨202´¦²¡±ä£©ÈéÄÚ¶¯ÂöÇŲ¡±ä»¼ÕßÐÐPCI£¬ÆäÖÐ63%£¨128´¦£©²¡±äλÓÚÎǺϿڣ¬91%£¨116´¦£©ÎǺϿڲ¡±ä²ÉÓþ­Æ¤¹Ú×´¶¯ÂöÇ»ÄÚ³ÉÐÎÊõ£¨PTCA£©£¬12´¦ÎǺϿÚÐÐÖ§¼ÜÖ²ÈëÊõ¡£½á¹ûÏÔʾ£ºÊÖÊõ³É¹¦ÂÊΪ97%£¬Ö÷ÒªÐÄÔ಻Á¼Ê¼þ£¨MACE£©ÂÊ1.7%£»Ëæ·Ã1ÄêËÀÍöÂÊ¡¢Ðļ¡¹£ËÀÂʺͰв¡±äѪÔËÖؽ¨£¨TLR£©ÂÊ·Ö±ðΪ4.4%¡¢2.9%ºÍ7.4%£¬ÆäÖÐÎǺϿڲ¡±äTLRÂÊΪ7%£¨PTCA×é¡¢BMS×é·Ö±ðΪ4.3%ºÍ33%£©¡£KockeritzµÈ·ÖÎöÁË31ÃûLIMAÎǺϿڲ¡±äµÄ»¼Õߣ¬18Ãû»¼Õ߳ɹ¦ÐÐPTCAÊõ£¬13ÃûÐÐÖ§¼ÜÖ²ÈëÊõ£¬Ëæ·ÃÁË6Ä꣬80% (8 of 10) Ö§¼ÜÖ²È뻼Õß³öÏÖÔÙÏÁÕ­£¬¶øÔÚPTCA×é½öÓÐ14%¡£(p=0.001)Ìáʾ£¬ÇòÄÒÀ©ÕÅ¿ÉÄܸüÊÊÓÃÓÚÈéÄÚ¶¯ÂöµÄÇÅѪ¹Ü½éÈëÖÎÁÆ¡£HungµÈÄÉÈë13ÀýÎǺϿÚÏÁÕ­µÄ»¼Õߣ¬7Ãû»¼ÕßÐÐPTCAÊõ£¬5Ãû»¼ÕßÐÐÖ§¼ÜÖ²ÈëÊõ£¬10Ãû»¼ÕßÔÚÊõºóÐйÚÂöÔìÓ°£¨ÆäÖÐ6ÃûÐÐPTCA£¬Æ½¾ùËæ·Ãʱ¼äÊÇ22¡À15.1Ô£©£¬Á½×é¸÷ÓÐ1Ãû»¼Õß³öÏÖÁËÔÙÏÁÕ­£¬¶Ô12Ãû»¼Õß½øÐÐÁÙ´²Ëæ·Ã34.5 ¡À20.9Ô£¬1ÃûËÀÓÚ¼±ÐÔÄÔ×äÖУ¬ÆäËû»¼ÕßÎÞÐĽÊÍ´µÄÖ¢×´¡£
Ä¿Ç°ÓйØÖ²ÈëDESÖÎÁƶ¯ÂöÇÅѪ¹ÜÎǺϿڲ¡±äµÄÑо¿½ÏÉÙ¡£BuchµÈÈëÑ¡ÈëÑ¡69Ãû»¼Õߣ¬ÆäÖÐ30Ãû»¼ÕßÖ²ÈëDES£¨21ÀýÊÇÎǺϿڲ¡±ä£©,39Ö²ÈëBMS£¨20ÀýΪÎǺϿڲ¡±ä£©£¬ÆÀ¹ÀDESºÍBMSÖÎÁÆLIMAÇÅѪ¹ÜµÄЧ¹û£¬½á¹ûÏÔʾ£¬Á½×éסԺÆڼ䡢1¸öÔºÍ6¸öÔÂÖ÷ÒªÖÕµãʼþ£¨ËÀÍö¡¢Ðļ¡¹£ËÀ¼°°ÐѪ¹ÜÖؽ¨£©·¢ÉúÂÊÎÞͳ¼Æѧ²î±ð£»ÓëBMS×éÏà±È£¬DES×é6¸öÔÂTLRÂÊÓнµµÍÇ÷ÊÆ£¨3.3% vs10%£¬P=0.38£©¡£¸ßÕ¹µÈ¶Ô13ÀýÈéÄÚ¶¯ÂöÇÅ£¨ÆäÖÐ12ÀýΪԶ¶ËÎǺϿڲ¡±ä£©Ö²ÈëDES£¬ËùÓл¼ÕßÍê³É6¸öÔÂÁÙ´²Ëæ·Ã, ÓÐ3ÀýÍê³ÉÔìÓ°Ëæ·Ã¡£Ö÷ÒªÐÄÔ಻Á¼Ê¼þ0%; ÎÞËÀÍö¡¢¼±ÐÔÐļ¡¹£ËÀ¡¢°ÐѪ¹ÜÔÙѪ¹Ü»¯ÖÎÁÆ¡£ÓÐ3Àý»¼ÕßÒò·Ç°Ð²¡±äÔÙ´ÎÐÐPCIÖÎÁÆ£¬ÌáʾDESÖÎÁÆÈéÄÚ¶¯ÂöÇÅѪ¹Ü²¡±äÊÇ°²È«¿É¿¿µÄ¡£ZavalloniµÈ±¨µÀÁË56ÃûÈéÄÚ¶¯ÂöÎǺϿڲ¡±äµÄ»¼Õߣ¬¹²52Ãû»¼Õߣ¨92.8%)Íê³ÉÁËPCIÊõ£¬ÆäÖÐ15Ãû»¼ÕßÐÐPTCAÊõ£¬37ÐÐÖ§¼ÜÖ²ÈëÊõ (17»¼ÕßÖ²ÈëDES,¶ø20Ö²ÈëBMS)£¬¹²50Ãû»¼ÕßÍê³É22.3¡À13.4ÔÂËæ·Ã£¬½á¹ûÏÔʾ£¬17.3%µÄ»¼ÕßÐèÒªTLR,Ö§¼ÜÖ²Èë×é½Ïµ¥´¿ÇòÄÒÀ©ÕÅ×é°ÐѪ¹Üʧ°ÜÂʸߣ¬µ«ÎÞͳ¼ÆѧÒâÒå (24.3% vs.6.7%; P=0.24).BMS×éËÀÍöÒ»ÈË£¬DES×éÓÐÈýÃû»¼Õß³öÏÖÐļ¡¹£ËÀ£¬BMS×éºÍDES×éTLRÎÞͳ¼Æѧ²îÒì (26.6% vs. 25%; P = 0.99).¶øDES×éÓÐÁ½Ãû»¼Õß³öÏÖÍíÆÚÖ§¼ÜѪ˨¡£²¢·ÖÎöDESÖÎÁÆÎǺϿڲ¡±äµÄÔ­ÒòÈçÏ£º£¨1£©1 ԭλѪ¹ÜºÍÇÅѪ¹ÜµÄ¶¯ÂöÖàÑù½øÕ¹²»Ò»Ñù£¬Òò´Ë¶ÔѪ¹Ü¡¢Ö§¼Ü¡¢¾ÛºÏÎï¼°Ò©Îï·´Ó¦²»Ò»Ñù£»£¨2£©ÓÉÓÚÐÄÔà¡¢·Î¼°ÇÅѪ¹Ü·Çͬ²½Ô˶¯²úÉúµÄ»úеÁ¦Ê¹Ö§¼ÜÍäÇú£¬Ò©Îï²»ÄÜÕý³£ÊÍ·ÅÖÁѪ¹Ü±Ú¡£ÁíÍ⣬ÎǺϿڲ¿Î»Ö÷ÒªÊÇÏËά×éÖ¯¶ø²»ÊÇÄÚĤÔöÉú£¬ÕâЩ¾ùÏÞÖÆÁËDESµÄÔ¤·ÀÔÙÏÁÕ­µÄ×÷Óá£
ÈéÄÚ¶¯ÂöÎǺϿڲ¡±äPCI·¾¶µÄÑ¡ÔñÓ¦¸Ã¸ù¾Ý»¼ÕߵľßÌåÇé¿ö¶ø¶¨¡£HungµÈÄÉÈë13ÀýÎǺϿÚÏÁÕ­µÄ»¼Õߣ¬6Ãû»¼Õß¾­¹É¶¯Âö£¬¶ø7Ãû»¼Õß¾­è㶯Âö£¬¾­³É¹¦ÐÐPCIÖÎÁÆ£¬Ìáʾ¾­è㶯ÂöºÍ¹É¶¯ÂöÐÐLIMAÇÅѪ¹Ü½éÈëÊÖÊõ°²È«µÄ¡£
×ÜÖ®£¬Ëæ×ÅÎÒ¹úCABG ÊõµÄ²»¶ÏÍƹãÓ¦ÓÃ, Òò¶¯¾²ÂöÇÅѪ¹ÜÏÁÕ­»ò±ÕÈû¶øÔٴξÍÕïµÄ²¡ÈËÒ²½«Ôö¶à£¬Æä»úÖƱȽϸ´ÔÓ£¬¿ÉÄÜÊÇÒ»¸ö¶àÒòËع²Í¬×÷ÓõĽá¹û£¬Òò´Ë£¬µ¥Ò»µÄÖÎÁÆ´ëÊ©ÁÆЧ²»¼Ñ£¬Õë¶Ô²»Í¬ÇÅѪ¹ÜÓÈÆäÊÇÎǺϿڲ¡±äµÄÌص㣬Ӧ¸Ã²ÉÓÃÊʵ±µÄPCIÖÎÁƲßÂÔ£¬µ±È»Ò²Ó¦¸Ã½ÌÓý»¼Õ߸ÄÉÆÉú»î·½Ê½£¬ºÏÀíµÄÒ©ÎïÖÎÁÆ£¬´Ó¶øʹ»¼Õß×î´ó³Ì¶È»ñÒæ¡£


²Î¿¼ÎÄÏ×
1  Brilakis ES, Wang TY, Rao SV,et al. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. J Am Coll Cardiol Intv 2010;3:1068 ¨C73
2  Abdel-Meguid AE, Whitlow PL, Simpfendorfer C, et al. Percutaneous revascularization of ostial saphenous vein graft stenoses. J Am Coll Cardiol. 1995 ;26(4):955-60.
3   Stephan WJ, Bates ER, Garratt KN, et al.Directional atherectomy of coronary  and saphenous vein graft ostial stenoses. Am J Cardiol. 1995 15;75(15):1015-8.
4  Eigler NL, Weinstock B, Douglas JS Jr, et al, for the ELCA Investigators. Excimer laser coronary angioplasty of aorta-as&l stenoses: results of the Excimer Laser Coronary Angioplasty (ELCA) Registry in the first 200 patients. Circulation 1993;88:2049-2057.
5 Nordrehaug JE, Priestley KA, Chronos NA, et al.Self expanding stents for the management of aorto-ostial stenoses in saphenous vein bypass grafts. Br Heart J. 1994 ;72(3):285-7.
6  Toutouzas K, Stankovic G, Takagi T,et al. Outcome of treatment of aorto-ostial  lesions involving the right coronary artery or a saphenous vein graft with a polytetrafluoroethylene-covered stent. Am J Cardiol. 2002 ,1;90(1):63-6.
7  Rechavia E, Litvack F, Macko G, et al. Stent implantation of saphenous vein graft aorto-ostial lesions in patients with unstable ischemic syndromes: immediate angiographic results and long-term clinical outcome. J Am Coil Cardiol 1995;25:866-70
8  Rocha-Singh K, Morris N, Wong SC,et al. Coronary stenting for treatment of ostial stenoses of native coronary arteries or aortocoronary saphenous venous grafts. Am J Cardiol. 1995,1;75(1):26-9.
9   Yamasaki M, Hara K, Masaki K,et al. Palmaz-Schatz stent implantation for aorto-ostial stenoses of native coronary arteries and saphenous vein grafts. J Cardiol. 1998;31(5):263-71.
10 Ahmed JM, Hong MK, Mehran R,et al. Comparison of debulking followed by stenting versus stenting alone for saphenous vein graft aortoostial lesions: immediate and one-year clinical outcomes J Am Coll Cardiol. 2000£»35(6):1560-8.
11  Kaplan S, Barlis P, Kiris A,et al. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions Acute Card Care. 2008;10(2):88-92.
12. Dorros G, Johnson WD, Tector AJ, Scmahl TM, Kalush SL, Janke L.
Percutaneous transluminal coronary angioplasty in patients with prior coronary artery bypass grafting. J Thorac Cardiovasc Surg 1984:87:17¨C26.
13. Reeder GS, Bresnahan JF, Holmes DR, Mock MB, Orszulak TA, Smith HC, Vlietstra RE. Angioplasty for aortocoronary bypass graft stenosis. Mayo Clin Proc 1986;61:14 ¨C19.
14  Douglas JS Jr, Gruentzig AR, King SB III, Hollman J, Ischinger T, Meier B, Craver JM, Jones EL, Wallere JL, Bone DK, Guyton R. Percutaneous  transluminal coronary angioplasty in patients with prior coronary bypass surgery. J Am Coll Cardiol 1983;2:745¨C754.
15 Platko WP, Hollman J, Whitlow PL, Franco I. Percutaneous  transluminal angioplasty of saphenous vein graft stenosis: long-term follow-up. J Am Coll Cardiol 1989;14:1645¨C1650.
16  De Feyter P, van Suylen R-J, de Jaegere PPT, Topol E, Serruys PW. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll  Cardiol 1993;21:1539 ¨C1549.
17  Gruberg L, Hong MK, Mehran R, et al. In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft   distal anastomosis site Am J Cardiol. 1999,15;84(12):1381-4.
18   Hearne SE, Davidson CJ, Zidar JP, et al.Internal mammary artery graft angioplasty: acute and long-term outcome. Cathet Cardiovasc Diagn, 1998 44:153¨C156.
19  Gruberg L, Dangas G, Mehran R, et al.Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes. J Am Coll Cardiol. 2000 35(4):944-948.
20   Köckeritz U, Reynen K, Knaut M, et. Results of angioplasty (with or without stent) at the site of a narrowed coronary anastomosis of the left internal mammary artery graft or via the internal mammary artery Am J Cardiol. 2004 15;93(12):1531-3.
21  Hung WC, Wu CJ, Yip HK,et al. Percutaneous  transluminal angioplasty to left internal mammary artery grafts: immediate and long-term clinical outcomes  Chang Gung Med J 2007;30:235-41
22  Buch AN, Xue Z, Gevorkian N, et al. Comparison of outcomes between bare metal stents and drug-eluting stents for percutaneous revascularization of internal mammary grafts Am J Cardiol 2006;98:722¨C724
23  ¸ßÕ¹ ³Â¼ÍÁÖ ÑîÔ¾½ø ÇÇÊ÷±öµÈ¡£Ò©ÎïÏ´ÍÑÖ§¼ÜÖÎÁÆ×óÈéÄÚ¶¯ÂöÇÅѪ¹Ü²¡±äµÄÁÙ´²Ñо¿ ÖйúÑ­»·ÔÓÖ¾ 2007, 22: 337-339.
24  Zavalloni D, Rossi ML, Scatturin M, et al. Drug-eluting stents for the percutaneous treatment of the anastomosis of the left internal mammary graft to left anterior descending artery. Coron Artery Dis.2007, 18£¨6£©:495¨C500
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

hb99doctor

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

Ö§³ÖһϰÉ
2Â¥2022-11-30 19:56:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌøת ÎÒÒª¶©ÔÄÂ¥Ö÷ hb99doctor µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍƼö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[ÂÛÎÄͶ¸å] Ͷ¸åÇóÖú 5+3 ÎÒÊÇÖÞÖÞ°¡ 2024-04-17 5/250 2024-04-18 17:13 by topedit
[Óлú½»Á÷] ¸µ¿Ëõ£»ù»¯£¬²úÂÊ´óÓÚ°Ù·ÖÖ®Ò»°Ù£¬Çó½â£¬ºÜ¼± 90+4 hsn991013 2024-04-15 10/500 2024-04-18 15:38 by lkw0604
[»ù½ðÉêÇë] ¹ú¼Ò×ÊÖú²©Ê¿ºóBCµµ³öУºó×ÊÖúµÄ¸ÅÂʶà´ó£¿ +3 ¿¨¿¨ÂÞÌØŶ 2024-04-16 3/150 2024-04-18 12:58 by wolfgangHugh
[ÂÛÎÄͶ¸å] The total environment¸ñʽ 25+4 lyyyyds0 2024-04-13 9/450 2024-04-18 09:33 by ÎÒΪÈËÈËÑÐ
[²©ºóÖ®¼Ò] ²©ºó½øÕ¾ÄêÁä¿ÉÒÔ³¬¹ý35Ëꣿ +8 suesong0818 2024-04-14 8/400 2024-04-18 08:38 by charles-c
[¿¼ÑÐ] 274Çóµ÷¼Á +7 Ëĸö´ó×Ö£¬ÄãµÎº 2024-04-14 10/500 2024-04-17 22:38 by »ª±±Áõ±ø
[ÎÞ»ú/Îﻯ] H3PO2ÔÚ130¶È¸½½ü·Ö½âΪÁ×»¯Ç⣨¾ç¶¾£©£¬ÔõÑù·À»¤£¬ÇóÖ¸µã¡£ 1(½ð±Ò+5) +3 ´óÁ¦2010 2024-04-13 9/450 2024-04-17 21:55 by ´óÁ¦2010
[¿¼ÑÐ] ¹¤Ñ§322£¬Ó¢ÓïÁù¼¶Çóµ÷¼Á +3 domax 2024-04-17 10/500 2024-04-17 21:25 by ¶«·½»¨Ô°Ð¡Íò
[¿¼²©] 25ÄêÉ격ÇóÖú£¬ÉäƵ·½Ïò +4 SherlockAH 2024-04-15 10/500 2024-04-16 18:06 by ljysudaee
[¿¼ÑÐ] 329Çóµ÷¼Á +6 Kaylawander 2024-04-13 7/350 2024-04-16 12:00 by ·çÀ´»¨¿ª1
[¿¼ÑÐ] ʳƷ¹¤³Ì¿¼Êýѧ283»¹ÄÜÓÐʲôµ÷¼ÁÑ¡Ôñ +7 ÓîÖæÎÞµÐÃÀÉÙÅ® 2024-04-12 8/400 2024-04-16 10:11 by cyclodextrin726
[¿¼ÑÐ] 322Çóµ÷¼Á +6 ±¾¼ºÉÏ°¶ 2024-04-15 7/350 2024-04-15 14:19 by mthwyj
[¿¼ÑÐ] 323Çóµ÷¼Á +15 °¡Q¾«Éñ¡« 2024-04-13 17/850 2024-04-14 12:44 by qjhawk
[¿¼ÑÐ] Ò»Ö¾Ô¸Öйú¿ÆѧԺ´óѧÉúÎïÓëҽҩרҵ£¬×Ü·Ö332£¬Çóµ÷¼Á¡£ +4 2114020553 2024-04-13 4/200 2024-04-13 17:21 by lincunhui
[¿¼ÑÐ] 290£¬Ò»Ö¾Ô¸±¨¿¼ÖØÇì´óѧÉúÎïÓëҽҩר˶£¬Çóµ÷¼Á +4 GPX4 2024-04-13 5/250 2024-04-13 17:19 by lincunhui
[¿¼ÑÐ] Çóµ÷¼Á +3 y1234567890. 2024-04-12 4/200 2024-04-13 11:24 by y1234567890.
[¿¼ÑÐ] 290 ÉúÎïÓëҽҩר˶£¨086000£©Çóµ÷¼Á +5 GPX4 2024-04-12 5/250 2024-04-13 07:48 by coco1981
[˶²©¼ÒÔ°] ÉúÎïÌ¿²É¹º +3 ½õÀð¸½Ìå@ 2024-04-12 3/150 2024-04-12 22:10 by Danny614
[¿¼ÑÐ] 294Çóµ÷¼Á +4 ÑåÑåyh 2024-04-12 7/350 2024-04-12 19:12 by ÑåÑåyh
[¿¼ÑÐ] 284Çóµ÷¼Á +5 15130653721 2024-04-12 6/300 2024-04-12 18:57 by qikanlunwen
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û